Trial Profile

CLERANCE HCC, Cabozantinib toLERANCE Study in HepatoCellular Carcinoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Liver cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CLERANCE; CLERANCE HCC

Most Recent Events

21 Jan 2023 Results(n=99) assessing safety and efficacy of Cabozantinib in pts with hepatocellular carcinoma presented at the 2023 Gastrointestinal Cancers Symposium
07 Nov 2021 Status changed from active, no longer recruiting to completed.
23 Nov 2020 Planned End Date changed from 1 Sep 2022 to 1 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com